{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:35:37Z","timestamp":1789763737392,"version":"4.0.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cpt.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:25:19Z","timestamp":1755876319000},"page":"208-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions"],"prefix":"10.1016","volume":"4","author":[{"given":"Aswini","family":"Rajendran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Elumalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranya","family":"Balasubramaniyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6259-5332","authenticated-orcid":false,"given":"Karthikeyan","family":"Elumalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2025.08.003_bib1","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.3390\/ijms22147371","article-title":"CXCL12-CXCR4\/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies","volume":"22","author":"Khare","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/2767-9764.CRC-22-0090","article-title":"Mavorixafor, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and inflammatory status of tumor microenvironment in patients with melanoma","volume":"2","author":"Andtbacka","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.cpt.2025.08.003_bib3","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2021-153346","article-title":"Global phase 3, randomized, placebo-controlled trial with open-label extension evaluating the oral CXCR4 antagonist mavorixafor in patients with WHIM syndrome (4WHIM): trial design and enrollment","volume":"138","author":"Dale","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.08.003_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood.2023022658","article-title":"A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome","volume":"144","author":"Badolato","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.08.003_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105415","article-title":"Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy","volume":"193","author":"M\u00e1rquez-Garb\u00e1n","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.cpt.2025.08.003_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.18585\/inabj.v14i4.2035","article-title":"Targeting metastatic cancer: disseminated tumor cells and premetastatic niches","volume":"14","author":"Meiliana","year":"2022","journal-title":"Indones Biomed J"},{"key":"10.1016\/j.cpt.2025.08.003_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-pharmtox-010919-023340","article-title":"The CXCL12\/CXCR4\/ACKR3 axis in the tumor microenvironment: Signalling, crosstalk, and therapeutic targeting","volume":"61","author":"Smit","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cpt.2025.08.003_bib8","article-title":"From gene modules to gene markers: an integrated AI-human approach selects CD38 to represent plasma cell-associated transcriptional signatures","volume":"12","author":"Kabeer","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117534","article-title":"CXCL12\/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis","volume":"249","author":"Mortezaee","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib10","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1182\/blood.2020007197","article-title":"The results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome","volume":"136","author":"Dale","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.08.003_bib11","first-page":"50","article-title":"A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis","volume":"5","author":"Anstine","year":"2019","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.cpt.2025.08.003_bib12","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/MS9.0000000000003030","article-title":"Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024","volume":"87","author":"Waheed","year":"2025","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.cpt.2025.08.003_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpt.2025.08.003_bib14","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cpt.2025.08.003_bib15","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2021-152990","article-title":"Oral administration of mavorixafor, a CXCR4 antagonist, increases peripheral white blood cell counts across different disease states","volume":"138","author":"Dale","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.08.003_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2025.08.003_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times","volume":"2","author":"Bailly","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.cpt.2025.08.003_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1410942","article-title":"Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy\u2014a review","volume":"15","author":"Muthuramalingam","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpt.2025.08.003_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202000136","article-title":"Latest advances for the sleeping beauty transposon system: 23 years of insomnia but prettier than ever","volume":"42","author":"Amberger","year":"2020","journal-title":"Bioessays"},{"key":"10.1016\/j.cpt.2025.08.003_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41417-021-00369-7","article-title":"Tumor suppressor immune gene therapy to reverse immunotherapy resistance","volume":"29","author":"Chada","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cpt.2025.08.003_bib21","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cpt.2025.08.003_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","article-title":"New insights into the correlations between circulating tumor cells and target organ metastasis","volume":"8","author":"Zhan","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2025.08.003_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000698","article-title":"Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumour therapy of BRAF-mutant thyroid cancer","volume":"8","author":"Crespo-Rodriguez","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cpt.2025.08.003_bib24","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1084\/jem.20190158","article-title":"Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis","volume":"216","author":"Dai","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib25","article-title":"Extracellular vesicles secreted by 3D tumor organoids are enriched in stemness-associated markers and modulate tumor microenvironment","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpt.2025.08.003_bib26","article-title":"Organoids in cancer therapies: a comprehensive review","volume":"13","author":"Li","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.cpt.2025.08.003_bib27","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1186\/s12903-024-04050-x","article-title":"Light gradient boosting-based prediction of quality of life among oral cancer-treated patients","volume":"24","author":"Ramalingam","year":"2024","journal-title":"BMC Oral Health"},{"key":"10.1016\/j.cpt.2025.08.003_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292965","article-title":"Genomic epidemiology analysis of drug-resistant Mycobacterium tuberculosis distributed in Mexico","volume":"18","author":"Mej\u00eda-Ponce","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.cpt.2025.08.003_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.omto.2022.06.002","article-title":"Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof of principle","volume":"26","author":"Gil","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.cpt.2025.08.003_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/jnt4010006","article-title":"Recent advancements, challenges, and future prospects in usage of nanoformulation as theranostics in inflammatory diseases","volume":"4","author":"Goyal","year":"2023","journal-title":"J Nanotheranostics"},{"key":"10.1016\/j.cpt.2025.08.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1219","article-title":"Spatiotemporally deciphering the mysterious mechanism of persistent HPV-induced malignant transition and immune remodelling from HPV-infected normal cervix, precancer to cervical cancer: integrating single-cell RNA-sequencing and spatial transcriptome","volume":"13","author":"Guo","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib32","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/cam4.5120","article-title":"Clinical spectrum of rectal cancer identifies hallmarks of early-onset patients and next-generation treatment strategies","volume":"12","author":"Shen","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signalling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2025.08.003_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fmars.2021.668771","article-title":"Integration of OMICS tools for understanding the fish immune response due to microbial challenge","volume":"8","author":"Natnan","year":"2021","journal-title":"Front Mar Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13073-022-01110-1","article-title":"Intratumor heterogeneity and T-cell exhaustion in primary CNS lymphoma","volume":"14","author":"Heming","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202011171","article-title":"Nanomedicine-boosting tumor immunogenicity for enhanced immunotherapy","volume":"31","author":"Huang","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.cpt.2025.08.003_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1576557","article-title":"Unveiling reverse vaccinology and immunoinformatics toward Saint Louis encephalitis virus: a ray of hope for vaccine development","volume":"16","author":"Ramalingam","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpt.2025.08.003_bib38","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ab7e73","article-title":"Efficacy evaluation and mechanism study on inhibition of breast cancer cell growth by multimodal targeted nanobubbles carrying AMD070 and ICG","volume":"31","author":"Shen","year":"2020","journal-title":"Nanotechnology"},{"key":"10.1016\/j.cpt.2025.08.003_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-024-01956-6","article-title":"Efficacy and safety of bispecific antibodies vs immune checkpoint blockade combination therapy in cancer: a real-world comparison","volume":"23","author":"Cheng","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cpt.2025.08.003_bib40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.62940\/als.v11i4.3504","article-title":"Mavorixafor: a spotlight on the clinical aspects and prospects of the first USFDA-approved treatment for the primary immunodeficiency WHIM syndrome","volume":"11","author":"Imran","year":"2024","journal-title":"Adv Life Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.26599\/NBE.2024.9290060","article-title":"Advances and prospects in integrated nano-oncology","volume":"16","author":"Jiang","year":"2024","journal-title":"Nano Biomed Eng"},{"key":"10.1016\/j.cpt.2025.08.003_bib42","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fonc.2019.01560","article-title":"Biomimetic nanoparticles camouflaged in cancer cell membranes and their applications in cancer theranostics","volume":"9","author":"Jin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2025.08.003_bib43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s42003-021-02070-9","article-title":"Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization","volume":"4","author":"J\u00f8rgensen","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.cpt.2025.08.003_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun"},{"key":"10.1016\/j.cpt.2025.08.003_bib45","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3375","article-title":"Tumor collection\/processing under physioxia uncovers highly relevant signalling networks and drug sensitivity","volume":"8","author":"Kumar","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.cpt.2025.08.003_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2025.08.003_bib48","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","article-title":"Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification","volume":"39","author":"Leader","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cpt.2025.08.003_bib49","doi-asserted-by":"crossref","DOI":"10.1063\/5.0194539","article-title":"Engineering approaches for understanding mechanical memory in cancer metastasis","volume":"8","author":"Lee","year":"2024","journal-title":"APL Bioeng"},{"key":"10.1016\/j.cpt.2025.08.003_bib50","article-title":"Targeting hypoxia: Hypoxia-Activated prodrugs in cancer therapy","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2025.08.003_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/159269","article-title":"Myeloid-derived suppressor cells and therapeutic strategies in cancer","volume":"2015","author":"Katoh","year":"2015","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.cpt.2025.08.003_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update","volume":"97","author":"Lakshman","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2025.08.003_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cbf.70011","article-title":"Bispecific antibodies, immune checkpoint inhibitors, and antibody\u2013drug conjugates directing antitumor immune responses: challenges and prospects","volume":"42","author":"Li","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.cpt.2025.08.003_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1483","article-title":"Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5 lipoxygenase dependent arachidonic acid pathway","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17425255.2020.1711884","article-title":"Clinical significance of chemokine receptor antagonists","volume":"16","author":"Miao","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cpt.2025.08.003_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodelling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cpt.2025.08.003_bib57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.cpt.2025.08.003_bib58","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3390\/ijms25074102","article-title":"Informed by cancer stem cells of solid tumors: advances in treatments targeting tumor-promoting factors and pathways","volume":"25","author":"MacLean","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ph17030351","article-title":"The current therapeutic landscape for metastatic prostate cancer","volume":"17","author":"Bernal","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cpt.2025.08.003_bib60","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.3390\/ijms25105374","article-title":"Chemokines as prognostic factor in colorectal cancer patients: a systematic review and meta-analysis","volume":"25","author":"Fellhofer-Hofer","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cpt.2025.08.003_bib62","article-title":"Conditional survival analysis and real-time prognosis prediction for prostate cancer patients","volume":"15","author":"Xu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpt.2025.08.003_bib63","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpt.2025.08.003_bib64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s40001-023-01181-9","article-title":"Multiomics analysis of DNA replication-associated primase polymerase (PRIMPOL) in pancancer: a potential target for prognosis and immune response","volume":"28","author":"Deng","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.cpt.2025.08.003_bib65","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.chest.2020.08.2043","article-title":"Clinical molecular imaging of pulmonary CXCR4 expression to predict outcome of pirfenidone treatment in idiopathic pulmonary fibrosis","volume":"159","author":"Derlin","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.cpt.2025.08.003_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/ped.2024.0062","article-title":"RASGRP1 deficiency associated with diffuse mesangial sclerosis infantile nephrotic syndrome and Epstein\u2013Barr virus-induced Hodgkin's lymphoma","volume":"38","author":"Nashrudin","year":"2025","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.cpt.2025.08.003_bib67","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/acs.accounts.0c00313","article-title":"Nanoscale metal\u2013organic frameworks for cancer immunotherapy","volume":"53","author":"Ni","year":"2020","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.cpt.2025.08.003_bib68","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.3390\/ijms25147743","article-title":"Advancements in personalized CAR-T therapy: comprehensive overview of biomarkers and therapeutic targets in hematological malignancies","volume":"25","author":"Olejarz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2025.08.003_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cpt.2025.08.003_bib70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cpt.2025.08.003_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003725","article-title":"Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite","volume":"10","author":"Renga","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cpt.2025.08.003_bib72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/hemato4020012","article-title":"BTK inhibitors and other targeted therapies in Waldenstr\u00f6m macroglobulinemia","volume":"4","author":"Chohan","year":"2023","journal-title":"Hemato"},{"key":"10.1016\/j.cpt.2025.08.003_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287863","article-title":"GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol","volume":"18","author":"Sukhtankar","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.cpt.2025.08.003_bib74","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/cancers13092018","article-title":"Overcoming the immunosuppressive tumor microenvironment in multiple myeloma","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2025.08.003_bib75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/1871520622666220523151409","article-title":"Boosting anti-tumour immunity using adjuvant apigenin","volume":"23","author":"Xiao","year":"2022","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.cpt.2025.08.003_bib76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12032-023-02233-0","article-title":"Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment","volume":"41","author":"Zhang","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.cpt.2025.08.003_bib77","article-title":"Therapeutic strategies for gastric cancer targeting immune cells: future directions","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpt.2025.08.003_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.126","article-title":"The role of neutrophil extracellular traps in cancer metastasis","volume":"10","author":"Wang","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib79","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2022-156216","article-title":"Mavorixafor for patients with chronic neutropenic disorders: results from a phase 1b, open-label, multicenter study","volume":"140","author":"Warren","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.08.003_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/acsnano.9b03978","article-title":"Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA\/siRNA nanotherapy","volume":"14","author":"Xie","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.cpt.2025.08.003_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1632","article-title":"Advances in engineering local drug delivery systems for cancer immunotherapy","volume":"12","author":"Abdou","year":"2020","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"10.1016\/j.cpt.2025.08.003_bib82","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12967-024-05347-9","article-title":"Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches","volume":"22","author":"Beheshtizadeh","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.cpt.2025.08.003_bib83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","article-title":"Development of pharmacological immunoregulatory anticancer therapeutics: current mechanistic studies and clinical opportunities","volume":"9","author":"Yin","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2025.08.003_bib84","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/abf7d5","article-title":"Nanocarrier-based drug delivery systems for bone cancer therapy: a review","volume":"16","author":"Prasad","year":"2021","journal-title":"Biomed Mater"},{"key":"10.1016\/j.cpt.2025.08.003_bib85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40364-025-00778-y","article-title":"Targeting the chemokine receptor CXCR4 for cancer therapies","volume":"13","author":"Rueda","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.cpt.2025.08.003_bib86","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41588-022-01157-1","article-title":"Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer","volume":"54","author":"Zhou","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.cpt.2025.08.003_bib87","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41435-022-00181-9","article-title":"Genotype\u2013phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4WHIM variants","volume":"23","author":"Zmajkovicova","year":"2022","journal-title":"Gene Immun"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294971322500093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294971322500093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:51:21Z","timestamp":1778935881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294971322500093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S294971322500093X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2025.08.003","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}